{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T07:05:29Z","timestamp":1784617529484,"version":"3.55.0"},"reference-count":77,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Polygenic risk scores (PRS) have emerged as a powerful tool to refine cancer risk prediction beyond age, family history, and modifiable environmental risk factors, enabling individualized prevention and early detection strategies. Evidence from breast, colorectal, and prostate cancer demonstrates that PRS significantly improve risk stratification in both sporadic and hereditary settings and can modify penetrance of pathogenic germline variants. Integrating PRS into multifactorial models such as CanRisk enhances predictive accuracy and supports risk-adapted preventive approaches. While implementation studies show feasibility, prospective validation and standardization as well as ancestry-specific calibration remain key challenges for clinical translation.<\/jats:p>","DOI":"10.1515\/medgen-2026-3011","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T15:57:23Z","timestamp":1783439843000},"page":"187-198","source":"Crossref","is-referenced-by-count":1,"title":["Polygenic risk scores in cancer"],"prefix":"10.1515","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9985-8397","authenticated-orcid":false,"given":"Anja","family":"T\u00fcchler","sequence":"first","affiliation":[{"name":"Institute for Hereditary Cancers Center for Integrated Oncology (CIO), Faculty of Medicine Cologne Germany"},{"name":"University of Cologne University Hospital Cologne Kerpener Str. 62 Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9453-7478","authenticated-orcid":false,"given":"Laura","family":"Grohs","sequence":"additional","affiliation":[{"name":"University of Bonn Institute of Human Genetics Medical Faculty Bonn Germany"},{"name":"University Hospital Bonn National Center for Hereditary Tumour Syndromes Venusberg-Campus 1 Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8505-0143","authenticated-orcid":false,"given":"Alexander","family":"Volk","sequence":"additional","affiliation":[{"name":"Institute for Hereditary Cancers Center for Integrated Oncology (CIO), Faculty of Medicine Cologne Germany"},{"name":"University of Cologne University Hospital Cologne Kerpener Str. 62 Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5228-1890","authenticated-orcid":false,"given":"Stefan","family":"Aretz","sequence":"additional","affiliation":[{"name":"University of Bonn Institute of Human Genetics Medical Faculty Bonn Germany"},{"name":"University Hospital Bonn National Center for Hereditary Tumour Syndromes Venusberg-Campus 1 Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"2026072106573421421_j_medgen-2026-3011_ref_001","doi-asserted-by":"crossref","unstructured":"Akdeniz BC, Morris AH, M\u00f8ller P et al. (2024) Evaluation of a combined model of Polygenic Risk Score and mismatch repair genes in the association of colorectal cancer for Norwegian cohort. Tumori: 3008916241303648","DOI":"10.1177\/03008916241303648"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_002","doi-asserted-by":"crossref","unstructured":"Archambault AN, Su Y-R, Jeon J et al. (2020) Cumulative Burden of Colorectal Cancer-Associated Genetic Variants Is More Strongly Associated With Early-Onset vs Late-Onset Cancer. Gastroenterology 158(5): 1274\u20131286.e12","DOI":"10.1053\/j.gastro.2019.12.012"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_003","doi-asserted-by":"crossref","unstructured":"Barnes DR, Silvestri V, Leslie G et al. (2022) Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. J Natl Cancer Inst 114(1): 109\u2013122","DOI":"10.1093\/jnci\/djab147"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_004","doi-asserted-by":"crossref","unstructured":"Borde J, Ernst C, Wappenschmidt B et al. (2021) Performance of Breast Cancer Polygenic Risk Scores in 760 Female CHEK2 Germline Mutation Carriers. J Natl Cancer Inst 113(7): 893\u2013899","DOI":"10.1093\/jnci\/djaa203"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_005","doi-asserted-by":"crossref","unstructured":"Brenner H, Stock C, Hoffmeister M (2014) Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. BMJ 348: g2467","DOI":"10.1136\/bmj.g2467"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_006","doi-asserted-by":"crossref","unstructured":"Carr PR, Weigl K, Edelmann D et al. (2020) Estimation of Absolute Risk of Colorectal Cancer Based on Healthy Lifestyle, Genetic Risk, and Colonoscopy Status in a Population-Based Study. Gastroenterology 159(1): 129\u2013138.e9","DOI":"10.1053\/j.gastro.2020.03.016"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_007","doi-asserted-by":"crossref","unstructured":"Castro E, Mikropoulos C, Bancroft EK et al. (2016) The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer. Oncologist 21(6): 716\u2013722","DOI":"10.1634\/theoncologist.2015-0336"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_008","doi-asserted-by":"crossref","unstructured":"Conti DV, Darst BF, Moss LC et al. (2021) Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet 53(1): 65\u201375","DOI":"10.1038\/s41588-020-00748-0"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_009","doi-asserted-by":"crossref","unstructured":"Daca Alvarez M, Quintana I, Terradas M et al. (2021) The Inherited and Familial Component of Early-Onset Colorectal Cancer. Cells 10(3)","DOI":"10.3390\/cells10030710"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_010","doi-asserted-by":"crossref","unstructured":"Dareng EO, Tyrer JP, Barnes DR et al. (2022) Polygenic risk modeling for prediction of epithelial ovarian cancer risk. Eur J Hum Genet 30(3): 349\u2013362","DOI":"10.1038\/s41431-021-00987-7"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_011","doi-asserted-by":"crossref","unstructured":"Due\u00f1as N, Klinkhammer H, Bonifaci N et al. (2023) Ability of a polygenic risk score to refine colorectal cancer risk in Lynch syndrome. J Med Genet 60(11): 1044\u20131051","DOI":"10.1136\/jmg-2023-109344"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_012","doi-asserted-by":"crossref","unstructured":"Esserman LJ, Fiscalini AS, Naeim A et al. (2026) Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial. JAMA 335(9): 763\u2013774","DOI":"10.1001\/jama.2025.24784"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_013","doi-asserted-by":"crossref","unstructured":"Fahed AC, Wang M, Homburger JR et al. (2020) Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions. Nat Commun 11(1): 3635","DOI":"10.1038\/s41467-020-17374-3"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_014","doi-asserted-by":"crossref","unstructured":"Feng X, Wang F, Yang W et al. (2022) Association Between Genetic Risk, Adherence to Healthy Lifestyle Behavior, and Thyroid Cancer Risk. JAMA Netw Open 5(12): e2246311","DOI":"10.1001\/jamanetworkopen.2022.46311"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_015","doi-asserted-by":"crossref","unstructured":"Fernandez-Rozadilla C, Timofeeva M, Chen Z et al. (2023) Author Correction: Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries. Nat Genet 55(3): 519\u2013520","DOI":"10.1038\/s41588-023-01334-w"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_016","doi-asserted-by":"crossref","unstructured":"Ficorella L, Yang X, Mavaddat N et al. (2025) Adapting the BOADICEA breast and ovarian cancer risk models for the ethnically diverse UK population. Br J Cancer 133(6): 844\u2013855","DOI":"10.1038\/s41416-025-03117-y"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_017","doi-asserted-by":"crossref","unstructured":"Gallagher S, Hughes E, Wagner S et al. (2020) Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes. JAMA Netw Open 3(7): e208501","DOI":"10.1001\/jamanetworkopen.2020.8501"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_018","doi-asserted-by":"crossref","unstructured":"Graff RE, Cavazos TB, Thai KK et al. (2021) Cross-cancer evaluation of polygenic risk scores for 16 cancer types in two large cohorts. Nat Commun 12(1): 970","DOI":"10.1038\/s41467-021-21288-z"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_019","doi-asserted-by":"crossref","unstructured":"Hassanin E, Spier I, Bobbili DR et al. (2023) Clinically relevant combined effect of polygenic background, rare pathogenic germline variants, and family history on colorectal cancer incidence. BMC Med Genomics 16(1): 42","DOI":"10.1186\/s12920-023-01469-z"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_020","doi-asserted-by":"crossref","unstructured":"Hemminki K, Hemminki O, Koskinen A et al. (2025) High familial risks in some rare cancers may pinpoint to hidden germline genetics: focus on esophageal, stomach, small intestinal, testis, thyroid and bone cancers. Hered Cancer Clin Pract 23(1): 9","DOI":"10.1186\/s13053-024-00303-6"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_021","unstructured":"Ho W-K, Tan M-M, Mavaddat N et al. (2020) European polygenic risk score for prediction of breast cancer shows similar performance in Asian women. Nat Commun 11(1): 3833"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_022","doi-asserted-by":"crossref","unstructured":"Hsu L, Jeon J, Brenner H et al. (2015) A model to determine colorectal cancer risk using common genetic susceptibility loci. Gastroenterology 148(7): 1330-9.e14","DOI":"10.1053\/j.gastro.2015.02.010"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_023","doi-asserted-by":"crossref","unstructured":"Huyghe JR, Bien SA, Harrison TA et al. (2019) Discovery of common and rare genetic risk variants for colorectal cancer. Nat Genet 51(1): 76\u201387","DOI":"10.1038\/s41588-018-0286-6"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_024","doi-asserted-by":"crossref","unstructured":"Huynh-Le M-P, Karunamuni R, Fan CC et al. (2022) Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. Prostate Cancer Prostatic Dis 25(4): 755\u2013761","DOI":"10.1038\/s41391-022-00497-7"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_025","doi-asserted-by":"crossref","unstructured":"Jenkins MA, Makalic E, Dowty JG et al. (2016) Quantifying the utility of single nucleotide polymorphisms to guide colorectal cancer screening. Future Oncol 12(4): 503\u2013513","DOI":"10.2217\/fon.15.303"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_026","doi-asserted-by":"crossref","unstructured":"Jeon J, Du M, Schoen RE et al. (2018) Determining Risk of Colorectal Cancer and Starting Age of Screening Based on Lifestyle, Environmental, and Genetic Factors. Gastroenterology 154(8): 2152\u20132164.e19","DOI":"10.1053\/j.gastro.2018.02.021"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_027","doi-asserted-by":"crossref","unstructured":"Jia G, Lu Y, Wen W et al. (2020) Evaluating the Utility of Polygenic Risk Scores in Identifying High-Risk Individuals for Eight Common Cancers. JNCI Cancer Spectr 4(3): pkaa021","DOI":"10.1093\/jncics\/pkaa021"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_028","doi-asserted-by":"crossref","unstructured":"Jiao S, Peters U, Berndt S et al. (2014) Estimating the heritability of colorectal cancer. Hum Mol Genet 23(14): 3898\u20133905","DOI":"10.1093\/hmg\/ddu087"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_029","doi-asserted-by":"crossref","unstructured":"Kachuri L, Graff RE, Smith-Byrne K et al. (2020) Pan-cancer analysis demonstrates that integrating polygenic risk scores with modifiable risk factors improves risk prediction. Nat Commun 11(1): 6084","DOI":"10.1038\/s41467-020-19600-4"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_030","doi-asserted-by":"crossref","unstructured":"Khera AV, Chaffin M, Aragam KG et al. (2018) Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet 50(9): 1219\u20131224","DOI":"10.1038\/s41588-018-0183-z"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_031","doi-asserted-by":"crossref","unstructured":"Kuchenbaecker KB, McGuffog L, Barrowdale D et al. (2017) Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst 109(7)","DOI":"10.1093\/jnci\/djw302"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_032","doi-asserted-by":"crossref","unstructured":"Lakeman IMM, Rodr\u00edguez-Girondo M, Lee A et al. (2020) Validation of the BOADICEA model and a 313-variant polygenic risk score for breast cancer risk prediction in a Dutch prospective cohort. Genet Med 22(11): 1803\u20131811","DOI":"10.1038\/s41436-020-0884-4"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_033","doi-asserted-by":"crossref","unstructured":"Lakeman IMM, van den Broek AJ, Vos JAM et al. (2021) The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genet Med 23(9): 1726\u20131737","DOI":"10.1038\/s41436-021-01198-7"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_034","doi-asserted-by":"crossref","unstructured":"Lakeman IMM, Rodr\u00edguez-Girondo MDM, Lee A et al. (2023) Clinical applicability of the Polygenic Risk Score for breast cancer risk prediction in familial cases. J Med Genet 60(4): 327\u2013336","DOI":"10.1136\/jmg-2022-108502"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_035","doi-asserted-by":"crossref","unstructured":"Law PJ, Studd J, Smith J et al. (2024) Systematic prioritization of functional variants and effector genes underlying colorectal cancer risk. Nat Genet 56(10): 2104\u20132111","DOI":"10.1038\/s41588-024-01900-w"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_036","doi-asserted-by":"crossref","unstructured":"Lecarpentier J, Silvestri V, Kuchenbaecker KB et al. (2017) Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. J Clin Oncol 35(20): 2240\u20132250","DOI":"10.1200\/JCO.2016.69.4935"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_037","doi-asserted-by":"crossref","unstructured":"Lee A, Mavaddat N, Wilcox AN et al. (2019) BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genet Med 21(8): 1708\u20131718","DOI":"10.1038\/s41436-018-0406-9"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_038","doi-asserted-by":"crossref","unstructured":"Lee A, Yang X, Tyrer J et al. (2022) Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors. J Med Genet 59(7): 632\u2013643","DOI":"10.1136\/jmedgenet-2021-107904"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_039","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Kolorektales Karzinom, Langversion 3.0, 2025, AWMF-Registernummer: 021-007OL. https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/kolorektales-karzinom\/. Zugriff am 24.2.2026"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_040","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Prostatakarzinom, Langversion 8.1, 2025, AWMF-Registernummer: 043-022OL. https:\/\/www.leitlinienprogrammonkologie.de\/leitlinien\/prostatakarzinom\/. Zugriff am 25.3.2026"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_041","doi-asserted-by":"crossref","unstructured":"Liu YL, Breen K, Catchings A et al. (2022) Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes. JCO Oncol Pract 18(3): 201\u2013209","DOI":"10.1200\/OP.21.00382"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_042","doi-asserted-by":"crossref","unstructured":"Li X, Timofeeva M, Spiliopoulou A et al. (2020) Prediction of colorectal cancer risk based on profiling with common genetic variants. Int J Cancer 147(12): 3431\u20133437","DOI":"10.1002\/ijc.33191"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_043","doi-asserted-by":"crossref","unstructured":"Loveday C, Law P, Litchfield K et al. (2018) Large-scale Analysis Demonstrates Familial Testicular Cancer to have Polygenic Aetiology. Eur Urol 74(3): 248\u2013252","DOI":"10.1016\/j.eururo.2018.05.036"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_044","doi-asserted-by":"crossref","unstructured":"Marmolejo DH, Wong MYZ, Bajalica-Lagercrantz S et al. (2021) Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe. Eur J Med Genet 64(12): 104350","DOI":"10.1016\/j.ejmg.2021.104350"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_045","doi-asserted-by":"crossref","unstructured":"Martin AR, Kanai M, Kamatani Y et al. (2019) Clinical use of current polygenic risk scores may exacerbate health disparities. Nat Genet 51(4): 584\u2013591","DOI":"10.1038\/s41588-019-0379-x"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_046","doi-asserted-by":"crossref","unstructured":"Mavaddat N, Michailidou K, Dennis J et al. (2019) Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. Am J Hum Genet 104(1): 21\u201334","DOI":"10.1016\/j.ajhg.2018.11.002"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_047","doi-asserted-by":"crossref","unstructured":"Mavaddat N, Ficorella L, Carver T et al. (2023) Incorporating Alternative Polygenic Risk Scores into the BOADICEA Breast Cancer Risk Prediction Model. Cancer Epidemiol Biomarkers Prev 32(3): 422\u2013427","DOI":"10.1158\/1055-9965.EPI-22-0756"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_048","doi-asserted-by":"crossref","unstructured":"McGeoch L, Saunders CL, Griffin SJ et al. (2019) Risk Prediction Models for Colorectal Cancer Incorporating Common Genetic Variants: A Systematic Review. Cancer Epidemiol Biomarkers Prev 28(10): 1580\u20131593","DOI":"10.1158\/1055-9965.EPI-19-0059"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_049","doi-asserted-by":"crossref","unstructured":"McHugh J, Bancroft E, Kote-Jarai Z et al. (2025) Prostate Cancer: genetics in practice now and in the future. Hered Cancer Clin Pract 23(1): 11","DOI":"10.1186\/s13053-025-00310-1"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_050","doi-asserted-by":"crossref","unstructured":"McHugh JK, Bancroft EK, Saunders E et al. (2025) Assessment of a Polygenic Risk Score in Screening for Prostate Cancer. N Engl J Med 392(14): 1406\u20131417","DOI":"10.1056\/NEJMoa2407934"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_051","doi-asserted-by":"crossref","unstructured":"Mur P, Bonifaci N, D\u00edez-Villanueva A et al. (2021) Non-Lynch Familial and Early-Onset Colorectal Cancer Explained by Accumulation of Low-Risk Genetic Variants. Cancers (Basel) 13(15)","DOI":"10.3390\/cancers13153857"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_052","doi-asserted-by":"crossref","unstructured":"Nusbaum DJ, Shi Z, Ashworth A et al. (2025) A polygenic risk score is associated with risk of bladder cancer and earlier age of diagnosis, independent of lifestyle factors. Urol Oncol 43(9): 523.e9-523.e17","DOI":"10.1016\/j.urolonc.2025.05.009"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_053","doi-asserted-by":"crossref","unstructured":"Nyberg T, Brook MN, Ficorella L et al. (2023) CanRisk-Prostate: A Comprehensive, Externally Validated Risk Model for the Prediction of Future Prostate Cancer. J Clin Oncol 41(5): 1092\u20131104","DOI":"10.1200\/JCO.22.01453"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_054","doi-asserted-by":"crossref","unstructured":"Padrik P, Puustusmaa M, T\u00f5nisson N et al. (2023) Implementation of Risk-Stratified Breast Cancer Prevention With a Polygenic Risk Score Test in Clinical Practice. Breast Cancer (Auckl) 17: 11782234231205700","DOI":"10.1177\/11782234231205700"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_055","doi-asserted-by":"crossref","unstructured":"Pashayan N, Antoniou AC, Ivanus U et al. (2020) Personalized early detection and prevention of breast cancer: ENVISION consensus statement. Nat Rev Clin Oncol 17(11): 687\u2013705","DOI":"10.1038\/s41571-020-0388-9"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_056","doi-asserted-by":"crossref","unstructured":"Pedersen LH, Bigaard J, Vejborg I et al. (2026) Risk Stratified Breast Cancer Screening: Early Outcomes and Psychological Impact from PRSONAL \u2013 a Randomized Clinical Trial. Breast 86: 104743","DOI":"10.1016\/j.breast.2026.104743"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_057","doi-asserted-by":"crossref","unstructured":"Petitjean C, Wilcox N, Ficorella L et al. (2025) Evaluating the performance of the Breast and Ovarian Analysis of Disease Incidence Algorithm model in predicting 10-year breast cancer risks in UK Biobank. J Natl Cancer Inst 117(5): 948\u2013958","DOI":"10.1093\/jnci\/djae335"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_058","unstructured":"Robert Koch-Institut und Deutsche Krebsregister e.V. (2025) Krebs in Deutschland f\u00fcr 2021 \u2013 2023. 15. Ausgabe"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_059","doi-asserted-by":"crossref","unstructured":"Rom\u00e1n M, Sala M, Domingo L et al. (2019) Personalized breast cancer screening strategies: A systematic review and quality assessment. PLoS One 14(12): e0226352","DOI":"10.1371\/journal.pone.0226352"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_060","doi-asserted-by":"crossref","unstructured":"Schmit SL, Edlund CK, Schumacher FR et al. (2019) Novel Common Genetic Susceptibility Loci for Colorectal Cancer. J Natl Cancer Inst 111(2): 146\u2013157","DOI":"10.1093\/jnci\/djy099"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_061","doi-asserted-by":"crossref","unstructured":"Schumacher FR, Al Olama AA, Berndt SI et al. (2018) Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet 50(7): 928\u2013936","DOI":"10.1038\/s41588-018-0142-8"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_062","doi-asserted-by":"crossref","unstructured":"Seibert TM, Fan CC, Wang Y et al. (2018) Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. BMJ 360: j5757","DOI":"10.1136\/bmj.j5757"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_063","doi-asserted-by":"crossref","unstructured":"Tamlander M, Jermy B, Sepp\u00e4l\u00e4 TT et al. (2024) Genome-wide polygenic risk scores for colorectal cancer have implications for risk-based screening. Br J Cancer 130(4): 651\u2013659","DOI":"10.1038\/s41416-023-02536-z"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_064","doi-asserted-by":"crossref","unstructured":"Thomas M, Sakoda LC, Hoffmeister M et al. (2020) Genome-wide Modeling of Polygenic Risk Score in Colorectal Cancer Risk. Am J Hum Genet 107(3): 432\u2013444","DOI":"10.1016\/j.ajhg.2020.07.006"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_065","doi-asserted-by":"crossref","unstructured":"Torkamani A, Wineinger NE, Topol EJ (2018) The personal and clinical utility of polygenic risk scores. Nat Rev Genet 19(9): 581\u2013590","DOI":"10.1038\/s41576-018-0018-x"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_066","doi-asserted-by":"crossref","unstructured":"T\u00fcchler A, Pauw A de, Ernst C et al. (2024) Clinical implications of incorporating genetic and non-genetic risk factors in CanRisk-based breast cancer risk prediction. Breast 73: 103615","DOI":"10.1016\/j.breast.2023.103615"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_067","doi-asserted-by":"crossref","unstructured":"van den Broek JJ, Schechter CB, van Ravesteyn NT et al. (2021) Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History. J Natl Cancer Inst 113(4): 434\u2013442","DOI":"10.1093\/jnci\/djaa127"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_068","doi-asserted-by":"crossref","unstructured":"Verras GI, Hamady ZZ, Collins A et al. (2025) Utility of Polygenic Risk Scores (PRSs) in Predicting Pancreatic Cancer: A Systematic Review and Meta-Analysis of Common-Variant and Mixed Scores with Insights into Rare Variant Analysis. Cancers (Basel) 17(2)","DOI":"10.3390\/cancers17020241"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_069","doi-asserted-by":"crossref","unstructured":"Wang A, Shen J, Rodriguez AA et al. (2023) Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants. Nat Genet 55(12): 2065\u20132074","DOI":"10.1038\/s41588-023-01534-4"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_070","doi-asserted-by":"crossref","unstructured":"Wang X, Dossus L, Gunter MJ et al. (2025) Risk Stratification for Endometrial Cancer Reveals Independent Contributions of Polygenic Risk and Body Mass Index. medRxiv","DOI":"10.1101\/2025.02.19.25322538"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_071","doi-asserted-by":"crossref","unstructured":"Weigl K, Thomsen H, Balavarca Y et al. (2018) Genetic Risk Score Is Associated With Prevalence of Advanced Neoplasms in a Colorectal Cancer Screening Population. Gastroenterology 155(1): 88\u201398.e10","DOI":"10.1053\/j.gastro.2018.03.030"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_072","doi-asserted-by":"crossref","unstructured":"Wei J, Mulford AJ, Shi Z et al. (2026) Monogenic and Polygenic Risk for Kidney Cancer in Two Large Biobanks. Eur Urol Oncol","DOI":"10.1016\/j.euo.2026.03.004"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_073","doi-asserted-by":"crossref","unstructured":"Yang X, Wu Y, Ficorella L et al. (2024) Validation of the BOADICEA model for epithelial tubo-ovarian cancer risk prediction in UK Biobank. Br J Cancer 131(9): 1473\u20131479","DOI":"10.1038\/s41416-024-02851-z"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_074","doi-asserted-by":"crossref","unstructured":"Yiangou K, Mavaddat N, Dennis J et al. (2024) Polygenic score distribution differences across European ancestry populations: implications for breast cancer risk prediction. Breast Cancer Res 26(1): 189","DOI":"10.1186\/s13058-024-01947-x"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_075","doi-asserted-by":"crossref","unstructured":"Young RP, Scott RJ, Callender T et al. (2025) Polygenic Risk Score Is Associated with Developing and Dying from Lung Cancer in the National Lung Screening Trial. J Clin Med 14(9)","DOI":"10.3390\/jcm14093110"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_076","doi-asserted-by":"crossref","unstructured":"Zhang YD, Hurson AN, Zhang H et al. (2020) Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. Nat Commun 11(1): 3353","DOI":"10.1038\/s41467-020-16483-3"},{"key":"2026072106573421421_j_medgen-2026-3011_ref_077","doi-asserted-by":"crossref","unstructured":"Zhu M, Zhu X, Han Y et al. (2025) Polygenic risk scores for pan-cancer risk prediction in the Chinese population: A population-based cohort study based on the China Kadoorie Biobank. PLoS Med 22(2): e1004534","DOI":"10.1371\/journal.pmed.1004534"}],"container-title":["Medizinische Genetik"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/medgen-2026-3011\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/medgen-2026-3011\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:57:57Z","timestamp":1784617077000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/medgen-2026-3011\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":77,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,7,8]]},"published-print":{"date-parts":[[2026,7,7]]}},"alternative-id":["10.1515\/medgen-2026-3011"],"URL":"https:\/\/doi.org\/10.1515\/medgen-2026-3011","relation":{},"ISSN":["1863-5490","0936-5931"],"issn-type":[{"value":"1863-5490","type":"electronic"},{"value":"0936-5931","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}